Quantcast
Last updated on April 18, 2014 at 7:13 EDT

Latest Unigene Stories

2013-08-05 08:27:56

Newly Launched Company Appoints Brian Zietsman as President and Chief Financial Officer, Nozer Mehta, Ph.D., as Chief Scientific Officer and Paul Shields, Ph.D., as Vice President of Operations BOONTON, N.J., Aug. 5, 2013 /PRNewswire/ -- Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced the official launch of its business, operational and development activities as the Company unveils enhancements to its clinically proven oral peptide...

2013-05-14 08:33:55

-Management to host conference call on May 14, 2013 at 11 a.m. ET- BOONTON, N.J., May 14, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE) today announced financial results for the first quarter ended March 31, 2013 and provided a corporate update on the Company's financial status and strategic initiatives. Ashleigh Palmer, Unigene's Chief Executive Officer, commented, "2013 has been extremely challenging for Unigene. The FDA advisory committee recommendation against...

2013-05-09 08:31:16

Agreement Provides Unigene with Immediate Capital Infusion, as Well as Potential Royalty and Milestone Payments BOONTON, N.J., May 9, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design and development of peptide-based therapeutics, today announced it has entered into an equity transfer and exclusive license agreement with Nordic Bioscience (Nordic) involving three proprietary metabolic peptide analogs for Type 2 diabetes, osteoarthritis and...

2013-04-08 08:30:45

- Victory Park Capital Commences Process for Potential Sale of Peptelligence(TM) Drug Delivery Platform - BOONTON, N.J., April 8, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the Company has entered into a second amendment to a financing agreement with affiliates of Victory Park Capital Advisors, LLC (VPC), whereby VPC has agreed to purchase an additional...

2013-03-11 20:22:46

-Management to host conference call on March 12, 2013 at 11 a.m. ET- BOONTON, N.J., March 11, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE) today announced financial results for the fourth quarter and full-year ended December 31, 2012 and provided a corporate update on the Company's financial status and the expected impact of the March 5, 2013 meeting of the Advisory Committee to the U.S. Food and Drug Administration. As noted in the Company's press release dated...

2013-03-06 16:26:46

BOONTON, N.J., March 6, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today commented on the outcome of the Food & Drug Administration (FDA) Advisory Committee Meeting held on March 5th, 2013 to discuss whether the benefit of calcitonin salmon for the treatment of postmenopausal osteoporosis outweighs a potential risk of cancer. The Advisory Committee concluded via a 12-9 vote that...

2013-02-13 12:26:43

BOONTON, N.J., Feb. 13, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE) today announced that for the second year in a row it has received the Drug Delivery Partnerships(TM) ("DDP") Innovation Award in the Industry Achievement category in recognition of the Company's 2012 clinical advances in the oral delivery of peptides. This year's DDP Award recipients were voted on and selected by conference attendees, including leading scientists, pharmaceutical executives and drug...

2013-02-13 08:28:23

BOONTON, N.J., Feb. 13, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE) today announced that for the second year in a row it has received the Drug Delivery Partnerships(TM) ("DDP") Innovation Award in the Industry Achievement category in recognition of the Company's 2012 clinical advances in the oral delivery of peptides. This year's DDP Award recipients were voted on and selected by conference attendees, including leading scientists, pharmaceutical executives and drug...

2013-02-07 08:27:56

BOONTON, N.J., Feb. 7, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that its Chief Scientific Officer, Nozer Mehta, Ph.D., will deliver an oral presentation on the value of Unigene's Peptelligence(TM) platform for oral peptide delivery at the 17th Annual Drug Delivery Partnerships in San Diego, CA. Dr. Mehta's presentation, Peptelligence, the Solution to Oral...

2013-01-15 12:27:34

BOONTON, N.J., Jan. 15, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the Food & Drug Administration (FDA) has posted notice of an Advisory Committee Meeting scheduled on March 5, 2013 to discuss whether the benefit of calcitonin salmon for the treatment of postmenopausal osteoporosis outweighs a potential risk of cancer. The Advisory Committee meeting is a...